Dulaglutide vs Semaglutide

How they're alike

Dulaglutide and semaglutide both act as agonists at the GLP-1 receptor, a Class B G-protein-coupled receptor expressed on pancreatic β-cells, hypothalamic appetite-control nuclei, the brainstem area postrema, and gastric smooth muscle (Chen 2025). Both incorporate the same engineering trick at residue 2 of the GLP-1(7-37) backbone — replacing alanine with α-aminoisobutyric acid (Aib) — to block DPP-4 cleavage at the His7–Ala8 scissile bond that destroys native GLP-1 within minutes of release. Their amino-acid sequences are ~93% identical over the 30-aa pharmacophore region, differing only at the Aib-position residue encoding and a single C-terminal substitution. The shared pharmacology produces a consistent set of effects in T2DM patients: glucose-dependent insulin secretion via Gαs/cAMP/PKA signaling in β-cells, suppression of glucagon from α-cells, slowed gastric emptying, and central satiety with reduced food intake (Jendle 2016). Both have demonstrated cardiovascular benefit in dedicated outcomes trials in type 2 diabetes — REWIND for dulaglutide (Gerstein 2019) and SUSTAIN-6 / SOUL for semaglutide — and both carry the GLP-1-class boxed warning against use in patients with personal or family history of medullary thyroid carcinoma or MEN-2.

How they differ

The decisive difference is how each molecule achieves once-weekly dosing, and the dose-response consequences that flow from that engineering choice. Dulaglutide is a large fusion biologic: two GLP-1(7-37) analog chains, each 30 amino acids with the Aib substitution, are covalently linked via short peptide connectors to an IgG4-Fc fragment, yielding a ~59.7 kDa homodimer. Half-life extension comes from FcRn-mediated recycling of the IgG4-Fc through endosomal compartments, giving a plasma t½ of approximately 4.5–5 days. The IgG4 subclass was specifically chosen because it does not fix complement and binds Fcγ receptors weakly, minimizing immunostimulatory potential. Semaglutide takes a smaller-molecule route: a single 31-residue peptide with the Aib substitution at position 2 plus an octadecandioic acid (C-18 fatty diacid) attached to the Lys26 side chain through a γ-glutamic-acid / miniPEG / γ-glutamic-acid linker. The fatty diacid binds reversibly to circulating albumin, extending half-life to ~1 week (Chen 2025).

The architectural difference cascades into clinical magnitude. In SUSTAIN 7 (Pratley 2018, cited as background in the Chen 2025 and Jendle 2016 reviews and across the meta-analyses in the dossier), once-weekly subcutaneous semaglutide at 0.5 mg and 1.0 mg produced larger reductions in both HbA1c and body weight than once-weekly dulaglutide at 0.75 mg and 1.5 mg. A 2025 systematic review and meta-analysis of head-to-head RCTs likewise concluded that semaglutide produced significantly greater HbA1c and FBS reductions than dulaglutide, while BMI and weight-change differences were less consistent across studies and dose ranges. Semaglutide is also available in formulations dulaglutide is not — an oral tablet (Rybelsus, SNAC-coformulated for daily use), a high-dose subcutaneous weight-management product (Wegovy 2.4 mg), and an oral 25 mg obesity product approved in late 2025 — while dulaglutide remains a subcutaneous-only weekly injection. Finally, the evidence-base scope is now markedly asymmetric: semaglutide carries FDA-approved indications spanning T2DM, chronic weight management, cardiovascular risk reduction in non-diabetic adults with established CVD, and non-cirrhotic MASH with stage 2–3 fibrosis (Wilding 2021, McGuire 2025), whereas dulaglutide's approved indications remain T2DM glycemic control and cardiovascular risk reduction in T2DM (Gerstein 2019, Jendle 2016).

Head-to-head clinical evidence

The principal direct comparison is the SUSTAIN 7 phase 3b randomized open-label trial of once-weekly subcutaneous semaglutide (0.5 mg, 1.0 mg) versus once-weekly dulaglutide (0.75 mg, 1.5 mg) in patients with type 2 diabetes. Across the dossier's review and meta-analytic sources, SUSTAIN 7 is consistently described as showing semaglutide superior to dulaglutide at matched-tier doses for both HbA1c reduction and body-weight reduction. The dulaglutide readme summarizes the same trial as the basis for its position that semaglutide and dulaglutide "are not interchangeable" molecules despite shared mechanism (Jendle 2016 review framing).

Beyond SUSTAIN 7, several smaller head-to-head and switch studies are present in the dossier's head-to-head candidate list. The COMING study (a Japanese multicentre randomized open-label trial published in 2023) directly compared the weekly GLP-1 RAs dulaglutide and semaglutide on clinical efficacy and safety in Japanese patients with type 2 diabetes. The PIONEER 10 phase 3a trial (2020) compared oral semaglutide with subcutaneous dulaglutide as the active comparator in Japanese T2DM patients, providing one of the few formal oral-vs-injectable head-to-head data sets between these molecules. Switch studies — including SWITCH-SEMA 1 (2023), a study of switching from liraglutide or dulaglutide to subcutaneous semaglutide, and a separate randomized switch trial published the same year — examined glycemic and treatment-satisfaction changes when patients transitioned between the two agents. A 2025 systematic review and meta-analysis pooled the head-to-head and switch evidence and reported that the pooled effect for switching from dulaglutide to semaglutide on weight change was not statistically significant (1.38, 95% CI –4.25 to 7.01), while HbA1c-reduction effects favoring semaglutide at matched dose tiers were more consistent across the included studies. More recent comparative-effectiveness work using target-trial-emulation methodology (Annals of Internal Medicine 2025) and pharmacoepidemiology data (Pharmacoepidemiology and Drug Safety 2025) has also examined cardiovascular effectiveness of semaglutide versus dulaglutide in real-world type 2 diabetes cohorts.

Safety profile comparison

The two drugs share the GLP-1-class adverse event signature, dominated by gastrointestinal effects in the first 4–8 weeks of therapy that attenuate with continued dosing. In semaglutide's STEP-1 obesity trial, aggregate GI adverse events occurred in 74.2% of treated patients versus 47.9% on placebo, with nausea (~40–44%), diarrhea (~30%), vomiting (~24%), constipation (~24%), and abdominal pain (~20%) the leading categories (Wilding 2021). The AWARD program for dulaglutide reported the same GI signature with broadly similar incidence and the same time-course of attenuation; in REWIND specifically, nausea occurred in 10.3% of dulaglutide-treated patients versus 5.0% on placebo, and diarrhea in 12.8% versus 10.4% (Gerstein 2019, Jendle 2016). Rare-but-serious events — acute pancreatitis, gallbladder events including cholecystitis, acute kidney injury during dehydration, and immune-mediated hypersensitivity — are reported across the GLP-1 class for both agents. Both agents carry the boxed warning against use in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, derived from rodent C-cell carcinogenicity findings without a confirmed human signal during the trialed observation windows.

Two safety-profile differences flow from the architecture rather than the pharmacology. First, immunogenicity: as a large IgG4-Fc fusion protein, dulaglutide can elicit anti-drug antibodies in a small fraction of patients, although the IgG4 subclass minimizes downstream complement and Fcγ-receptor activation, and trial data did not show attenuation of efficacy or immune-mediated adverse events (Jendle 2016 review). Semaglutide, as a small acylated peptide, does not present the same antibody-formation profile. Second, the post-marketing surveillance footprint is much larger for semaglutide because of the scale of obesity-indication exposure (Wegovy) and the consequent litigation around severe gastroparesis cases (US multidistrict litigation since 2023) — these signals are not symmetric to dulaglutide, which has remained a T2DM-only product.

Indication overview

Dulaglutide (Trulicity) is FDA-approved for glycemic control in adults with type 2 diabetes (approved September 2014, based on the AWARD phase 3 program) and for cardiovascular risk reduction in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors (indication added September 2020, based on REWIND; Gerstein 2019). It is supplied as the Trulicity autoinjector pen at 0.75 mg and 1.5 mg once-weekly doses, with higher investigational doses (3.0 mg, 4.5 mg) studied but not introduced into routine use.

Semaglutide carries a broader and more recent set of approvals: Ozempic for type 2 diabetes (2017); Rybelsus oral tablet for type 2 diabetes (2019); Wegovy for chronic weight management in adults and adolescents ≥12 (2021); Wegovy expansion for reduction of major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease without diabetes (March 2024, based on SELECT); Wegovy accelerated approval for non-cirrhotic MASH with stage 2–3 fibrosis (August 2025, based on ESSENCE part 1); and an oral Wegovy 25 mg tablet approved in late 2025 for adults with overweight or obesity (Wilding 2021, McGuire 2025). Semaglutide is the only GLP-1 receptor agonist with both an injectable obesity indication and an oral formulation.

In the dossier's literature, semaglutide is presented as the agent with the larger clinical effect on HbA1c and weight at the head-to-head dose comparisons studied to date, and the larger and broader evidence base across cardiometabolic indications. Dulaglutide retains its position as a once-weekly T2DM treatment with the REWIND cardiovascular outcome data — notable for including a substantial subgroup of patients without established CVD at baseline — and a long-running real-world track record since 2014.